The FDA has rejected an investigational liver cancer regimen combining HLB Co.’s rivoceranib with Jiangsu Hengrui’s camrelizumab for a third time, citing manufacturing deficiencies tied to a facility inspection. The repeated complete response letter underscores continued regulatory friction for checkpoint–TKI combinations in HCC, even as sponsors seek revised submissions to address the underlying quality issues.